Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA developing "industry rights" document on retaliation, agency tells Sen. Gregg.

This article was originally published in The Tan Sheet

Executive Summary

FDA "INDUSTRY RIGHTS" DOCUMENT ON RETALIATION/DISPUTE RESOLUTION will be developed by the agency's Chief Mediator and Ombudsman Office, FDA Commissioner David Kessler said in a June 29 letter to Sen. Judd Gregg (R-N.H.). "In order to enhance the industry's knowledge and use" of the Ombudsman office, which Kessler described as a "resource" for problem resolution between industry and the agency, the commissioner has directed the office "to prepare a document that will outline industry's rights and describe the agency's processes for both retaliation and dispute resolution."





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts